2022 AACR Annual Meeting News: Kipp Weiskopf, Whitehead Fellow at MIT, presented a poster “Targeted therapies prime lung cancer cells for macrophage-mediated destruction” highlighting work done in collaboration with the Hata Lab that suggests that blocking CD47 on tumor cells may improve the response to lung cancer targeted therapies.
The Hata lab was well represented with two oral presentations at the 2022 AACR Annual Meeting in New Orleans. Hideko Isozaki presented “Impact of therapy induced APOBEC3A mutagenesis on tumor evolution in non small cell lung cancer” highlighting a new mechanism by which targeted therapies may induce mechanisms that facilitate evolution of acquired resistance. Chendi Li presented “LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRAS G12C + MCL-1 blockade,” describing a novel mechanism by which LKB1 loss leads to a targetable therapeutic vulnerability in KRAS mutant lung cancers and providing rationale for clinical testing of KRAS G12C + MCL-1 inhibitors in this patient population.”
